Dr. Mark Blaskovich is a Principal Investigator and Program Coordinator for the Community for Open Antimicrobial Drug Discovery, and a Senior Research Officer at the Institute for Molecular Bioscience at The University of Queensland. Since starting at The University of Queensland in 2010, Mark has been working on developing new antibiotics to treat drug resistant pathogens and the use of modified antibiotics to detect bacterial infections. He has extensive medicinal chemistry expertise and over 15 years of industrial drug development experience, most recently as Chief Operating Officer of Mimetica. He has published over fifty research articles, authored ‘The Handbook on Syntheses of Amino Acids’, and is an inventor on ten patent families with over 100 granted and pending applications.
What does the conference theme “Do More” mean to you?
Think creatively about new approaches to solving health issues.
Why are you excited about participating in MM2017?
Multidisciplinary interaction with key stakeholders such as pharmacists is critical to solving the problems surrounding antimicrobial resistance.
Where do you see pharmacy in 10 years?
Becoming more integrated in patient care and management of their drugs.